One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis

被引：0
作者：
Alessandro Inno
Sandro Barni
Antonio Ghidini
Alberto Zaniboni
Fausto Petrelli
机构：
[1] IRCCS Ospedale Sacro Cuore Don Calabria,Oncology Unit, Cancer Care Center
[2] ASST Bergamo Ovest,Oncology Unit, Medical Sciences Department
[3] Casa di Cura Igea,Oncology Unit
[4] Casa di Cura Poliambulanza,Oncology Unit
来源：
Breast Cancer Research and Treatment | 2019年 / 173卷
关键词：
Breast cancer; Adjuvant; Trastuzumab; Duration; One year;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：247 / 254
页数：7
相关论文
共 72 条
  • [1] Slamon DJ(1987)Human breast cancer: correlation of relapse and survival with amplification of the HER-2lneu Oncogene Science 353 1659-1672
  • [2] Clark GM(2005)Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 1673-1684
  • [3] Wong SG(2005)Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 365 1273-1283
  • [4] Levin WJ(2011)Adjuvant trastuzumab in HER2-positive breast cancer N Engl J Med 32 3744-3752
  • [5] Ullrich A(2014)Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2–positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831 J Clin Oncol 382 1021-1028
  • [6] McGuire WL(2007)2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial Lancet 354 809-820
  • [7] Piccart-Gebhart MJ(2011)Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial Lancet Oncol 27 5685-5692
  • [8] Procter M(2017)11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the Herceptin adjuvant (HERA) trial Lancet 339 b2535-b2535
  • [9] Leyland-Jones B(2013)2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial Lancet 17 1-12
  • [10] Romond EH(2006)Adjuvant cocetaxel or vinorelbine with or without trastuzumab for breast cancer N Engl J Med 327 557-560
12345678